3 research outputs found
Novel Insights into the Mechanism of Inhibition of MmpL3, a Target of Multiple Pharmacophores in Mycobacterium tuberculosis
MmpL3, a resistance-nodulation-division (RND) superfamily transporter, has been implicated in the formation of the outer
membrane of Mycobacterium tuberculosis; specifically, MmpL3 is required for the export of mycolic acids in the form of trehalose
monomycolates (TMM) to the periplasmic space or outer membrane of M. tuberculosis. Recently, seven series of inhibitors
identified by whole-cell screening against M. tuberculosis, including the antituberculosis drug candidate SQ109, were shown to
abolish MmpL3-mediated TMM export. However, this mode of action was brought into question by the broad-spectrum activities
of some of these inhibitors against a variety of bacterial and fungal pathogens that do not synthesize mycolic acids. This observation,
coupled with the ability of three of these classes of inhibitors to kill nonreplicating M. tuberculosis bacilli, led us to
investigate alternative mechanisms of action. Our results indicate that the inhibitory effects of adamantyl ureas, indolecarboxamides,
tetrahydropyrazolopyrimidines, and the 1,5-diarylpyrrole BM212 on the transport activity of MmpL3 in actively replicating
M. tuberculosis bacilli are, like that of SQ109, most likely due to their ability to dissipate the transmembrane electrochemical
proton gradient. In addition to providing novel insights into the modes of action of compounds reported to inhibit MmpL3,
our results provide the first explanation for the large number of pharmacophores that apparently target this essential inner
membrane transporter
Synthesis and Properties of N-(R-Adamantan-1-ylalkyl)-N′-[3(4)-fluorophenyl]thioureas—Target-Oriented Human Soluble Epoxide Hydrolase (hsEH) Inhibitors
Kinase Targets for Mycolic Acid Biosynthesis in Mycobacterium tuberculosis.
Mycolic acids (MAs) are the characteristic, integral building blocks for the mycomembrane belonging to the insidious bacterial pathogen Mycobacterium tuberculosis (M.tb). These C60-C90 long a-alkyl-Ăź-hydroxylated fatty acids provide protection to the tubercule bacilli against the outside threats, thus allowing its survival, virulence and resistance to the current antibacterial agents. In the post-genomic era, progress has been made towards understanding the crucial enzymatic machineries involved in the biosynthesis of MAs in M.tb in which two discrete fatty acid synthases systems (FAS-I and FAS-II) were discovered. However, gaps still remain in the exact role of the phosphorylation and dephosphorylation regulatory mechanisms within these systems. To date, a total of 11 serine-threonine protein kinases (STPKs) are found in M.tb. Most enzymes implicated in the MAs synthesis were found to be phosphorylated in vitro and/or in vivo. For instance, phosphorylation of KasA, KasB, mtFabH, HadAB/BC, InhA, MabA, FadD32 and PcA downregulated their enzymatic activity, while phosphorylation of VirS increased its enzymatic activity. These observations suggest that the kinases and phosphatases system could play a role in M.tb adaptive responses and survival mechanisms in the human host. As the mycobacterial STPKs do not share a high sequence homology to the human's, there has been some early drug discovery efforts towards developing potent and selective inhibitors as novel antitubercular agents. Recent updates to the kinases and phosphatases involved in the regulation of MAs biosynthesis will be presented in this minireview, including their known small molecule inhibitors